Becton, Dickinson and Company $BDX Position Reduced by Asset Management One Co. Ltd.

Key Points

• Asset Management One reduced its BDX position by 3.6% in the third quarter, selling 5,044 shares and retaining 136,374 shares valued at approximately $24.4 million. Institutional investors collectively own 86.97% of the company.
• BDX insiders sold 6,907 shares worth about $1.27 million over the past 90 days, including sales by CEO Thomas Polen and EVP Michael Feld under pre-arranged Rule 10b5-1 plans.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $185.07. BDX recently reported quarterly EPS of $3.23, topping estimates, while revenue rose 5.4% year over year to $4.98 billion.

Asset Management One Co. Ltd. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,374 shares of the medical instruments supplier's stock after selling 5,044 shares during the period. Asset Management One Co. Ltd.'s holdings in Becton, Dickinson and Company were worth $24,411,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Brown Lisle Cummings Inc. increased its stake in Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock worth $97,000 after purchasing an additional 54 shares during the period. Pension & Wealth Management Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 12.3% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier's stock valued at $94,000 after purchasing an additional 56 shares during the period. Elevation Point Wealth Partners LLC boosted its stake in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC increased its stake in shares of Becton, Dickinson and Company by 1.1% in the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock worth $834,000 after buying an additional 62 shares during the period. Finally, Trifecta Capital Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 62 shares during the period. 86.97% of the stock is owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,907 shares of company stock worth $1,269,128 over the last ninety days. 0.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 21st. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Jefferies Financial Group restated a "buy" rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $185.07.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $198.57 on Friday. The firm has a market capitalization of $54.71 billion, a price-to-earnings ratio of 15.01, a PEG ratio of 13.16 and a beta of 0.21. The stock has a fifty day moving average of $186.38 and a 200 day moving average of $170.29. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm earned $3.68 EPS. The company's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.